BSE filing, NSE: MANGALAM. Summary written from the filing by ALFA Finder's alert engine.
Mangalam Drugs and Organics Ltd: key numbers
- Share price
- ₹29.11
- Market cap
- ₹46.08 Cr
- Revenue (annual)
- ₹232.1 Cr
- Net profit (annual)
- ₹-44.40 Cr
- P/E (TTM)
- -1.2×Sector 46.1×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mangalam Drugs and Organics Ltd
All →Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs issued a postal ballot notice seeking approval to re-appoint Praveen Saxena as independent director for a second five-year term. Voting closes 17 June 2026.
Mangalam Drugs and Organics Debt & Borrowing: ₹1,557 Cr
Mangalam Drugs and Organics Limited has reported a default amounting to Rs.1,557.27 Crore. The company has submitted a restructuring proposal to its banks to manage the obligation.
- Value
- ₹1,557 Cr
Mangalam Drugs and Organics Debt & Borrowing: ₹15.57 Cr
Mangalam Drugs and Organics Limited reported defaults on bank loan obligations totaling Rs. 15.57 Crore. The defaults involve cash credit accounts at Bank of Maharashtra and Bank of Baroda.
- Value
- ₹15.57 Cr
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs and Organics Limited has issued a Postal Ballot notice to seek shareholder approval for appointing Shri Prabhakar Raghunath Zavar as an Independent Director. The appointment is for five years.
Mangalam Drugs and Organics Management Change
Manglam Drugs and Organics Ltd. has appointed M/s S.N. Nanda & Co. as Statutory Auditor and M/s L.N. Joshi & Co. as Secretarial Auditor.
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs and Organics Ltd held its 53rd Annual General Meeting on September 23, 2026. The meeting transacted standard business items including financial statement adoption and auditor appointments.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.